FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
DECEMBER 2017

POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.
HEMATOLOGY
PAPER-II
HEM/D/17/48/II
Time 3 hours
Max. Marks :100
• Attempt all questions in order.
• Each question carries 10 marks.
• Read the question carefully and answer to the point neatly and legibly.
• Do not leave any blank pages between two answers.
• Indicate the question number correctly for the answer in the margin space
• Answer all the parts of a single question together.
• Start the question to a question on a fresh page or leave adequate space between two answers.
• Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. Neutrophil function tests
Chediak Higashi syndromes
Granulocyte transfusions

2. Management of idiopathic hypereosinophilic syndrome
Role of PDGRFα in hypereosinophilia
Acquired eosinophilia

3. Diagnosis of systemic mastocytosis
Granules of basophils
Causes of basophilia in peripheral blood.

4. Diagnosis of chronic myelomonocytic leukemia
(CMML).
How does it differ from MDS with excess blasts?
Management of CMML
Infections causing monocytosis.

5. Histomonophagocytic Syndrome:
What are the causes?
Criteria for diagnosis
Langerhan's cell histiocytosis.

6. Chronic lymphocytic leukemia:
Diagnosis of CLL
How to distinguish it from monoclonal B
lymphocytosis.
The genetic landscape of CLL and the implications in
prognosis.
Current management of CLL

FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
DECEMBER 2017

POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.

7. Plasma cells:
What are the imaging techniques for the diagnosis of
bone disease in multiple myeloma and their
advantages/disadvantages?
Criteria for the diagnosis of multiple myeloma,
smoldering multiple myeloma and MGUS.
How to differentiate between multiple myeloma and
lymphoplamacytic lymphoma?

8. What is hemovigilance?
How will you implement this in blood bank?
5+5
9. Risk stratification in MDS
Treatment options in low risk MDS
5+5
10. Acquired causes of thrombocytosis
JAK 2 pathway and its inhibitors in myeloproliferative
neoplasms
Management of essential thrombocythemia